Aim: To investigate the impact of natremia in metastatic colorectal cancer (mCRC) patients treated with aflibercept plus folinic acid, 5-fluorouracil, oxaliplatin and irinotecan (FOLFIRI). Patients & methods: A total of 84 mCRC patients receiving aflibercept plus FOLFIRI as second-line treatment were enrolled and divided into two groups based on their median sodium value. Progression-free survival and overall survival were analyzed. Results: Patients with sodium levels ≥140 mEq/l had significantly longer median progression-free survival (4.1 vs 2 months; p < 0.01) and median overall survival (12 vs 7.3 months; p < 0.01) compared with those with lower levels. Conclusion: This study suggests that higher pretreatment serum sodium levels are associated with improved outcomes in mCRC patients receiving aflibercept and FOLFIRI, potentially serving as a prognostic marker to aid treatment management.

Plain language summary

What is this article about?

Colorectal cancer (CRC) is a common and deadly disease. Despite advances in treatment options, the prognosis remains poor for patients who progress beyond the first-line therapy. Antiangiogenic therapy, which targets blood vessel growth in tumors, has become an important treatment approach for metastatic CRC (mCRC). Aflibercept is a drug used in combination with chemotherapy to treat mCRC patients who have progressed after initial treatment. However, there is limited knowledge about factors that can predict the effectiveness of this treatment. This study aimed to investigate the relationship between sodium levels and treatment outcomes in 84 mCRC patients receiving aflibercept and chemotherapy as second-line therapy.

What were the results?

The results showed that patients with baseline sodium levels of ≥140 mEq/l had significantly longer progression-free survival and overall survival compared with patients with lower sodium levels. This finding suggests that baseline serum sodium levels could serve as a prognostic factor for survival outcomes in mCRC patients treated with aflibercept and chemotherapy. Other factors associated with better survival outcomes included longer survival without disease progression after first-line chemotherapy, receiving maintenance treatment with aflibercept and completing more treatment cycles.

What do the results of the study mean?

This study highlights the potential significance of serum sodium levels as a predictor of treatment effectiveness in mCRC patients. Further research is needed to confirm these findings and better understand the underlying mechanisms. Evaluating serum sodium levels could be a useful tool in predicting outcomes and improving treatment strategies for mCRC patients.

Tweetable abstract

Higher pretreatment sodium levels associated with longer progression-free and overall survival in mCRC patients receiving aflibercept plus FOLFIRI. #ColorectalCancer #Aflibercept #FOLFIRI #SurvivalOutcomes.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
MedlineGoogle Scholar
2. Morris VK, Kennedy EB, Baxter NN et al. Treatment of metastatic colorectal cancer: ASCO guideline. J. Clin. Oncol. 41(3), 678–700 (2023).
MedlineGoogle Scholar
3. Benson AB, Venook AP, Al-Hawary MM et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw. 19(3), 329–359 (2021).
MedlineGoogle Scholar
4. Raica M, Cimpean AM, Ribatti D. Angiogenesis in pre-malignant conditions. Eur. J. Cancer 45(11), 1924–1934 (2009).
Medline CASGoogle Scholar
5. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 144(5), 646–674 (2011).
Medline CASGoogle Scholar
6. Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 30(28), 3499–3506 (2012). •• This article is of significant interest as it has led to the introduction of a new therapeutic option for patients with pretreated colon cancer using oxaliplatin.
Medline CASGoogle Scholar
7. Loupakis F, Antonuzzo L, Bachet JB et al. Practical considerations in the use of regorafenib in metastatic colorectal cancer. Ther. Adv. Med. Oncol. 12, 1758835920956862 (2020).
Google Scholar
8. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335–2342 (2004).
Medline CASGoogle Scholar
9. Tabernero J, Yoshino T, Cohn AL et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 16(5), 499–508 (2015).
Medline CASGoogle Scholar
10. Cremolini C, Loupakis F, Antoniotti C et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 16(13), 1306–1315 (2015).
Medline CASGoogle Scholar
11. Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 30(28), 3499–3506 (2012). •• This article is of significant interest as it has led to the introduction of a new therapeutic option for patients with pre-treated colon cancer using oxaliplatin.
Medline CASGoogle Scholar
12. Erol C, Sendur MAN, Bilgetekin I et al. Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: real-life data from Turkish oncology group. J. Cancer Res. Ther. 18(12 Suppl. 2), 347–353 (2022).
Google Scholar
13. Fernández Montes A, Martínez Lago N, Covela Rúa M et al. Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers. Cancer Med. 8(3), 882–889 (2019).
MedlineGoogle Scholar
14. Ivanova JI, Saverno KR, Sung J et al. Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA. Med. Oncol. 34(12), 193 (2017).
MedlineGoogle Scholar
15. Palmer BF, Gates JR, Lader M. Causes and management of hyponatremia. Ann. Pharmacother. 37(11), 1694–1702 (2003).
MedlineGoogle Scholar
16. Berghmans T, Paesmans M, Body JJ. A prospective study on hyponatraemia in medical cancer patients: Epidemiology, aetiology and differential diagnosis. Support Care Cancer 8(3), 192–197 (2000).
Medline CASGoogle Scholar
17. Hansen O, Sørensen P, Hansen KH. The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period. Lung Cancer 68(1), 111–114 (2010).
MedlineGoogle Scholar
18. Castillo JJ, Vincent M, Justice E. Diagnosis and management of hyponatremia in cancer patients. Oncologist 17(6), 756–765 (2012). • Explains the importance of accurately diagnosing and effectively treating cancer patients with hyponatremia, given its negative prognostic implications.
MedlineGoogle Scholar
19. Abu Zeinah GF, Al-Kindi SG, Hassan AA, Allam A. Hyponatraemia in cancer: association with type of cancer and mortality. Eur. J. Cancer Care (Engl.) 24(2), 224–231 (2015).
MedlineGoogle Scholar
20. Roviello G, Catalano M, De Giorgi U et al. Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors. Front. Oncol. 12, 918413 (2022).
Medline CASGoogle Scholar
21. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228–247 (2009).
Medline CASGoogle Scholar
22. NIH/NCI. Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP. Protocol 147 (2017). https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm
Google Scholar
23. Decoster J, Gallucci M, Iselin A-MR. Best practices for using median splits, artificial categorization, and their continuous alternatives. J. Exp. Psychopathol. JEP 2, 197–209 (2011).
Google Scholar
24. Kim J, Kim H, Hong JY et al. Prognostic factors of survival with aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as second-line therapy for patients with metastatic colorectal cancer. J. Cancer 12(2), 460–466 (2021).
Medline CASGoogle Scholar
25. Hamaguchi T, Denda T, Kudo T et al. Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer. Cancer Sci. 110(11), 3565–3572 (2019).
Medline CASGoogle Scholar
26. Nozue M, Oshiro Y, Kurata M et al. Treatment and prognosis in colorectal cancer patients with bone metastasis. Oncol. Rep. 9(1), 109–112 (2002).
MedlineGoogle Scholar
27. Park HS, Chun YJ, Kim HS et al. Clinical features and KRAS mutation in colorectal cancer with bone metastasis. Sci. Rep. 10(1), 21180 (2020).
Medline CASGoogle Scholar
28. Tabernero J, Van Cutsem E, Lakomý R et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur. J. Cancer 50(2), 320–331 (2014).
Medline CASGoogle Scholar
29. Sandfeld-Paulsen B, Aggerholm-Pedersen N, Winther-Larsen A. Hyponatremia as a prognostic factor in non-small cell lung cancer: a systematic review and meta-analysis. Transl. Lung Cancer Res. 10(2), 651–661 (2021).
Medline CASGoogle Scholar
30. Schutz FAB, Xie W, Donskov F et al. The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium. Eur. Urol. 65(4), 723 (2014).
Medline CASGoogle Scholar
31. Kim HS, Yi SY, Jun HJ et al. Clinical outcome of gastric cancer patients with bone marrow metastases. Oncology 73(3–4), 192–197 (2007).
MedlineGoogle Scholar
32. Djamgoz MBA. Hyponatremia and cancer progression: possible association with sodium-transporting proteins. Bioelectricity 2(1), 14 (2020). •• Highly interesting article that elucidates a potential new mechanism associated with hyponatremia in cancer.
MedlineGoogle Scholar

Vol. 19, No. 38

Metrics

Downloaded 39 times

History

Received 17 July 2023

Accepted 13 November 2023

Published online 5 December 2023

Published in print December 2023

Information

Keywords

Author contributions

G Roviello: conceptualization, methodology, software; M Catalano and D Lavacchi: data curation, writing-original draft preparation; S Shabani, A Guidolin, M Ramello and E Giommoni: visualization, investigation; L Antonuzzo, R Petrioli: supervision; S Pillozzi and M Brugia: software, validation; M Catalano: writing-reviewing and editing.

Financial disclosure

The authors have no financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, stock ownership or options and expert testimony.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download

Prognostic role of sodium levels in colorectal cancer patients receiving aflibercept plus FOLFIRI

Abstract